RxDoctor Payments DataLook up a doctor →

Tayler Long, MD

Critical Care Medicine · Plano, TXNPI 1699743401

Payments from drug & device makers

$13,404in general payments, 2019–2025

Across 660 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$1K
  • Mallinckrodt Hospital Products Inc.$853
  • Mylan Specialty L.p.$827
  • Boehringer Ingelheim$784
  • Merck$698
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$13,20298%
  • Education$2022%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,404 in reported general payments places this provider in the 90th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$160,382
Medicare patients
473
Services billed
1,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate18$241,473
Trelegy ElliptaFluticasone/Umeclidin/Vilanter163$127,440
Breztri AerosphereBudesonide/Glycopyr/Formoterol51$39,254
EliquisApixaban47$28,046
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$16,523
Spiriva HandihalerTiotropium Bromide23$15,864
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$6,130
Advair HfaFluticasone Propion/Salmeterol19$6,039
Breo ElliptaFluticasone/Vilanterol11$5,902
Incruse ElliptaUmeclidinium Bromide13$4,526
Tiotropium Bromide11$3,935
Albuterol Sulfate HfaAlbuterol Sulfate100$3,274
Levalbuterol Tartrate HfaLevalbuterol Tartrate11$1,435
Theophylline ErTheophylline Anhydrous17$760
Montelukast Sodium101$575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$784$241,47318 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$2,276$154,391201 claims
AstraZenecaBreztri Aerosphere$1,486$39,25451 claims
PfizerEliquis$124$28,04647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →